HOME
|
NEWSROOM
|
CONTACT US
| SEARCH
Welcome
Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules are designed to "find, treat and follow"™ malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.
LEARN MORE
News Update
FDA Clears Cellectar's IND Application for Lead Drug Candidate
Charles C. Harwood, Jr., Joins Cellectar, Inc.’s Board of Directors
Charles C. Harwood, Jr. has joined the Cellectar Board of Directors.
Cellectar, Inc. Begins GMP Production
Radiopharmaceutical production facility to support clinical development for lead drug candidate and other molecules.
©Cellectar, LLC | All Rights Reserved |
info@cellectar.com
|
Site Credit
